Recent Updates
Recently added Catalysts

SL1002

Phase 3

Osteoarthritis Knee Pain | Small molecule | Pain |cbdMD, Inc.|Last Updated: Aug 25, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment150

FDA Designations

No designations recorded

Clinical trial landscape

SL1002 · 1 trial · 1 indication

Phase 3 1
NCT07226258Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee PainOsteoarthritis Knee Pain
RECRUITING150 Analytics
PHASE3RECRUITING
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
Osteoarthritis Knee PainUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline to Week 12 in the Weekly Mean of the Average Daily Pain Intensity While Walking
Baseline to week 12

The pain intensity score is measured using a numeric rating scale (NRS)

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
SL1002EXPERIMENTALSL1002
PlaceboPLACEBO_COMPARATORNormal saline

Interventions

NameTypeDescription
SL1002DRUGSL1002 injectable solution
Normal SalineDRUGNormal Saline
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria includes: 1. Male or female patients ≥ 40 years of age 2. Body Mass Index (BMI) limits 3. Chronic knee pain resulting from osteoarthritis 4. Kellgren-Lawrence Grade 2 (mild) or Grade 3 (moderate) 5. Baseline KOOS pain 6. Patients taking baseline analgesics 7. Diagnostic nerve blo...

Countries:United States
Unlock Eligibility Criteria